A model-informed drug discovery and development strategy played a key role in the novel glucose-responsive insulin MK-2640's early clinical development strategy and supported a novel clinical trial paradigm to assess glucose responsiveness. The development and application of in silico modeling approaches by leveraging substantial published clinical insulin pharmacokinetic-pharmacodynamic (PKPD) data and emerging preclinical and clinical data enabled rapid quantitative decision making. Learnings can be applied to define PKPD properties of novel insulins that could become therapeutically meaningful for diabetic patients.

中文翻译：

---

新型葡萄糖反应性胰岛素MK-2640的模型信息化药物发现和开发策略可实现快速决策。

在新的葡萄糖反应性胰岛素MK-2640的早期临床开发策略中，模型通知的药物发现和开发策略起着关键作用，并支持评估葡萄糖反应性的新的临床试验范式。通过充分利用已发表的临床胰岛素药代动力学-药效学（PKPD）数据以及新兴的临床前和临床数据，计算机模拟方法的开发和应用实现了快速的定量决策。可以将学习应用于定义新型胰岛素的PKPD特性，这些新特性对于糖尿病患者可能具有治疗意义。